Genomic Health Stock Price, News & Analysis (NASDAQ:GHDX)

$33.28 5.28 (18.86 %)
(As of 12/15/2017 01:13 AM ET)
Previous Close$28.00
Today's Range$27.97 - $34.18
52-Week Range$26.37 - $34.18
Volume1.24 million shs
Average Volume123,332 shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.66

About Genomic Health (NASDAQ:GHDX)

Genomic Health logoGenomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.

Receive GHDX News and Ratings via Email

Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GHDX
CUSIP37244C10
Phone650-556-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio3.74%
Quick Ratio3.74%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$327.87 million
Price / Sales3.53
Cash FlowN/A
Price / CashN/A
Book Value$4.66 per share
Price / Book7.14

Profitability

Trailing EPS($0.12)
Net Income$-13,910,000.00
Net Margins-1.30%
Return on Equity-1.79%
Return on Assets-1.41%

Miscellaneous

Employees846
Outstanding Shares34,780,000

Genomic Health (NASDAQ:GHDX) Frequently Asked Questions

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) posted its earnings results on Tuesday, November, 1st. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The medical research company had revenue of $82.30 million for the quarter, compared to analysts' expectations of $83.24 million. Genomic Health had a negative return on equity of 1.79% and a negative net margin of 1.30%. The firm's quarterly revenue was up 11.8% compared to the same quarter last year. During the same period last year, the business posted ($0.36) earnings per share. View Genomic Health's Earnings History.

When will Genomic Health make its next earnings announcement?

Genomic Health is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Genomic Health.

Where is Genomic Health's stock going? Where will Genomic Health's stock price be in 2017?

8 Wall Street analysts have issued 1 year target prices for Genomic Health's shares. Their predictions range from $25.00 to $39.00. On average, they expect Genomic Health's stock price to reach $31.57 in the next twelve months. View Analyst Ratings for Genomic Health.

Who are some of Genomic Health's key competitors?

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:

  • Kimberly J. Popovits, Chairman of the Board, President, Chief Executive Officer
  • Gordon Bradley Cole, Chief Financial Officer, Chief Operating Officer
  • Steven Shak M.D., Chief Scientific Officer
  • Phillip Febbo M.D., Chief Medical Officer
  • Laura Leber Kammeyer, Chief Communications Officer
  • Frederic Pla Ph.D., Chief Business and Product Development Officer
  • , Bio & Compensation - 
  • James Vaughn, Chief Commercial Officer
  • , Bio & Compensation - 
  • Julian C. Baker, Lead Independent Director
  • Felix J. Baker Ph.D., Independent Director
  • Fred E. Cohen Ph.D. M.D., Independent Director

Who owns Genomic Health stock?

Genomic Health's stock is owned by a number of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (1.45%), Eagle Asset Management Inc. (1.01%), American Century Companies Inc. (0.51%), Prudential Financial Inc. (0.51%), Cowen Prime Services LLC (0.36%) and Citadel Advisors LLC (0.27%). Company insiders that own Genomic Health stock include Felix Baker, Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo, Randall S Livingston and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Who sold Genomic Health stock? Who is selling Genomic Health stock?

Genomic Health's stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Oppenheimer & Co. Inc., Prudential Financial Inc. and California State Teachers Retirement System. Company insiders that have sold Genomic Health company stock in the last year include Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health.

Who bought Genomic Health stock? Who is buying Genomic Health stock?

Genomic Health's stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, American Century Companies Inc., Cowen Prime Services LLC, Los Angeles Capital Management & Equity Research Inc., GSA Capital Partners LLP, Public Employees Retirement System of Ohio, Point72 Asset Management L.P. and Nordea Investment Management AB. View Insider Buying and Selling for Genomic Health.

How do I buy Genomic Health stock?

Shares of Genomic Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of Genomic Health stock can currently be purchased for approximately $33.28.

How big of a company is Genomic Health?

Genomic Health has a market capitalization of $1.05 billion and generates $327.87 million in revenue each year. The medical research company earns $-13,910,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. Genomic Health employs 846 workers across the globe.

How can I contact Genomic Health?

Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]


MarketBeat Community Rating for Genomic Health (GHDX)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  427
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Genomic Health (NASDAQ:GHDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.902.002.002.00
Ratings Breakdown: 3 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.13$32.00$31.29$32.50
Price Target Upside: 3.58% upside12.76% upside0.68% downside1.82% upside

Genomic Health (NASDAQ:GHDX) Consensus Price Target History

Price Target History for Genomic Health (NASDAQ:GHDX)

Genomic Health (NASDAQ:GHDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/13/2017J P Morgan Chase & CoDowngradeNeutral -> Underweight$25.00HighView Rating Details
11/15/2017Canaccord GenuityReiterated RatingBuy$39.00N/AView Rating Details
10/20/2017Jefferies GroupReiterated RatingHold$34.00N/AView Rating Details
9/1/2017CowenReiterated RatingHold$34.00LowView Rating Details
8/3/2017Piper Jaffray CompaniesReiterated RatingHold$31.00LowView Rating Details
5/3/2017Raymond James FinancialReiterated RatingOutperform -> Market PerformHighView Rating Details
1/18/2017Deutsche BankReiterated RatingHold$31.00N/AView Rating Details
1/9/2017BarclaysReiterated RatingSell$27.00N/AView Rating Details
8/3/2016Bank of AmericaSet Price TargetSell$28.00N/AView Rating Details
6/21/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Genomic Health (NASDAQ:GHDX) Earnings History and Estimates Chart

Earnings by Quarter for Genomic Health (NASDAQ:GHDX)

Genomic Health (NASDAQ GHDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$0.08N/AView Earnings Details
8/1/2017Q2 2017($0.06)($0.08)$86.08 million$85.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.06)($0.07)$86.21 million$84.00 millionViewListenView Earnings Details
2/14/2017Q416($0.01)$0.04$84.08 million$82.70 millionViewListenView Earnings Details
11/1/2016Q316($0.09)($0.08)$83.24 million$82.30 millionViewN/AView Earnings Details
8/2/2016Q216($0.18)($0.18)$81.27 million$81.97 millionViewN/AView Earnings Details
5/4/2016Q1($0.24)($0.19)$78.12 million$80.89 millionViewN/AView Earnings Details
2/10/2016Q415($0.09)($0.10)$74.03 million$74.50 millionViewListenView Earnings Details
11/3/2015Q315($0.18)($0.36)$73.35 million$73.60 millionViewN/AView Earnings Details
8/4/2015Q215($0.27)($0.29)$71.65 million$70.60 millionViewListenView Earnings Details
5/5/2015Q115($0.28)($0.30)$69.30 million$68.15 millionViewN/AView Earnings Details
2/10/2015Q414($0.21)($0.20)$72.20 million$69.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.22)($0.20)$71.00 million$69.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.28)($0.15)$69.04 million$70.50 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.24)$68.47 million$67.00 millionViewN/AView Earnings Details
2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView Earnings Details
2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView Earnings Details
11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView Earnings Details
8/8/2012($0.02)$0.06ViewN/AView Earnings Details
5/2/2012($0.02)$0.02ViewN/AView Earnings Details
2/6/2012$0.09$0.08ViewN/AView Earnings Details
11/1/2011$0.03$0.10ViewN/AView Earnings Details
8/3/2011$0.02$0.08ViewN/AView Earnings Details
5/3/2011$0.02($0.01)ViewN/AView Earnings Details
2/8/2011$0.06$0.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Genomic Health (NASDAQ:GHDX) Earnings Estimates

2017 EPS Consensus Estimate: ($0.02)
2018 EPS Consensus Estimate: $0.29
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.08)$0.02($0.03)
Q2 20172($0.07)($0.07)($0.07)
Q3 20172($0.01)$0.02$0.01
Q4 20172$0.07$0.08$0.08
Q1 20182$0.07$0.07$0.07
Q2 20182$0.02$0.07$0.05
Q3 20182$0.07$0.07$0.07
Q4 20182$0.08$0.13$0.11
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Genomic Health (NASDAQ:GHDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Genomic Health (NASDAQ GHDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 46.20%
Institutional Ownership Percentage: 89.76%
Insider Trades by Quarter for Genomic Health (NASDAQ:GHDX)
Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Genomic Health (NASDAQ GHDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/12/2017G Bradley ColeCOOSell5,000$29.94$149,700.00View SEC Filing  
11/7/2017G Bradley ColeCOOSell5,000$31.47$157,350.00View SEC Filing  
11/2/2017James J. VaughnInsiderSell1,379$32.51$44,831.29View SEC Filing  
10/10/2017G Bradley ColeCOOSell5,000$31.93$159,650.00View SEC Filing  
9/14/2017Kimberly J. PopovitsInsiderSell5,000$31.00$155,000.00View SEC Filing  
9/12/2017G Bradley ColeCOOSell5,000$31.86$159,300.00View SEC Filing  
8/14/2017Kimberly J. PopovitsInsiderSell5,000$30.22$151,100.00View SEC Filing  
8/8/2017G Bradley ColeCOOSell5,000$30.57$152,850.00View SEC Filing  
8/8/2017James J. VaughnInsiderSell8,000$30.59$244,720.00View SEC Filing  
7/19/2017Phillip G. FebboInsiderSell3,174$33.57$106,551.18View SEC Filing  
7/11/2017G Bradley ColeCOOSell5,000$32.53$162,650.00View SEC Filing  
7/5/2017Kimberly J. PopovitsInsiderSell5,000$32.59$162,950.00View SEC Filing  
7/5/2017Kimberly J. PopovitsCEOSell1,468$32.67$47,959.56View SEC Filing  
6/23/2017Steven ShakInsiderSell5,000$33.27$166,350.00View SEC Filing  
6/5/2017Kimberly J. PopovitsInsiderSell5,000$32.32$161,600.00View SEC Filing  
5/23/2017Steven ShakInsiderSell5,000$29.40$147,000.00View SEC Filing  
5/19/2017Fred E CohenDirectorSell8,250$29.54$243,705.00View SEC Filing  
5/18/2017Fred E CohenDirectorSell16,500$29.88$493,020.00View SEC Filing  
5/16/2017Fred E CohenDirectorSell8,250$30.68$253,110.00View SEC Filing  
5/3/2017Kimberly J. PopovitsInsiderSell5,000$31.77$158,850.00View SEC Filing  
4/24/2017Steven ShakInsiderSell5,000$31.46$157,300.00View SEC Filing  
4/3/2017Kimberly J. PopovitsInsiderSell5,000$31.30$156,500.00View SEC Filing  
3/23/2017Steven ShakInsiderSell5,000$31.26$156,300.00View SEC Filing  
3/20/2017Laura LeberInsiderSell3,072$31.88$97,935.36View SEC Filing  
3/6/2017Kimberly J. PopovitsInsiderSell5,000$31.09$155,450.00View SEC Filing  
2/16/2017Phillip G. FebboInsiderSell2,495$30.09$75,074.55View SEC Filing  
1/23/2017Steven ShakInsiderSell5,000$27.28$136,400.00View SEC Filing  
1/10/2017G Bradley ColeCOOSell5,000$29.22$146,100.00View SEC Filing  
12/5/2016Kimberly J PopovitsInsiderSell5,000$30.02$150,100.00View SEC Filing  
11/3/2016Kimberly J PopovitsInsiderSell5,313$28.88$153,439.44View SEC Filing  
10/11/2016Steven ShakInsiderSell5,000$30.39$151,950.00View SEC Filing  
10/10/2016G Bradley ColeCOOSell8,290$30.59$253,591.10View SEC Filing  
10/6/2016James J. VaughnInsiderSell3,000$29.68$89,040.00View SEC Filing  
9/13/2016Steven ShakInsiderSell5,000$26.83$134,150.00View SEC Filing  
8/23/2016Steven ShakInsiderSell5,000$27.24$136,200.00View SEC Filing  
8/15/2016Felix BakerDirectorBuy100,000$27.02$2,702,000.00View SEC Filing  
8/11/2016G Bradley ColeCOOSell5,000$28.87$144,350.00View SEC Filing  
8/8/2016James J. VaughnInsiderSell3,000$28.74$86,220.00View SEC Filing  
7/19/2016Steven ShakInsiderSell5,000$27.42$137,100.00View SEC Filing  
7/6/2016G Bradley ColeCOOSell5,000$26.64$133,200.00View SEC Filing  
6/21/2016Steven ShakInsiderSell5,000$25.77$128,850.00View SEC Filing  
6/9/2016G Bradley ColeCOOSell5,000$26.62$133,100.00View SEC Filing  
6/6/2016James J VaughnInsiderSell1,997$28.00$55,916.00View SEC Filing  
5/16/2016G Bradley ColeCOOSell5,000$27.60$138,000.00View SEC Filing  
5/10/2016Phillip G FebboInsiderSell6,324$27.20$172,012.80View SEC Filing  
5/4/2016Steven ShakInsiderSell10,000$25.43$254,300.00View SEC Filing  
1/13/2016Randall S. LivingstonDirectorSell1,250$32.14$40,175.00View SEC Filing  
1/12/2016G Bradley ColeCOOSell4,000$31.69$126,760.00View SEC Filing  
1/7/2016James J. VaughninsiderSell2,000$33.63$67,260.00View SEC Filing  
12/8/2015G Bradley ColeCOOSell4,000$29.26$117,040.00View SEC Filing  
12/7/2015James J. VaughninsiderSell2,000$29.33$58,660.00View SEC Filing  
11/10/2015G Bradley ColeCOOSell4,000$26.03$104,120.00View SEC Filing  
9/9/2015G Bradley ColeCOOSell9,664$25.35$244,982.40View SEC Filing  
7/7/2015G Bradley ColeCOOSell4,000$27.53$110,120.00View SEC Filing  
6/9/2015G Bradley ColeCOOSell4,000$26.24$104,960.00View SEC Filing  
4/13/2015Kimberly J PopovitsCEOSell3,000$31.28$93,840.00View SEC Filing  
4/7/2015G Bradley ColeCOOSell4,000$30.44$121,760.00View SEC Filing  
2/2/2015Randall S LivingstonDirectorSell1,000$31.93$31,930.00View SEC Filing  
1/12/2015Kimberly J PopovitsCEOSell3,000$33.46$100,380.00View SEC Filing  
12/8/2014G Bradley ColeCOOSell4,336$32.52$141,006.72View SEC Filing  
11/12/2014Kimberly J PopovitsCEOSell4,300$34.82$149,726.00View SEC Filing  
10/13/2014Kimberly J PopovitsCEOSell3,000$30.78$92,340.00View SEC Filing  
10/8/2014G Bradley ColeCOOSell4,000$28.77$115,080.00View SEC Filing  
9/11/2014Kimberly J PopovitsCEOSell3,000$29.82$89,460.00View SEC Filing  
9/8/2014G Bradley ColeCOOSell4,700$30.09$141,423.00View SEC Filing  
8/14/2014Steven ShakEVPSell13,348$27.36$365,201.28View SEC Filing  
8/13/2014Steven ShakEVPSell7,000$27.25$190,750.00View SEC Filing  
7/14/2014Kimberly J PopovitsCEOSell3,000$26.59$79,770.00View SEC Filing  
7/8/2014G Bradley ColeCOOSell2,300$27.05$62,215.00View SEC Filing  
7/1/2014Steven ShakEVPSell7,000$27.00$189,000.00View SEC Filing  
4/14/2014Steven ShakEVPSell7,000$26.25$183,750.00View SEC Filing  
4/8/2014G Bradley ColeCOOSell3,000$27.00$81,000.00View SEC Filing  
3/14/2014Steven ShakEVPSell7,000$28.36$198,520.00View SEC Filing  
2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.56View SEC Filing  
1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00View SEC Filing  
1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00View SEC Filing  
12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.00View SEC Filing  
12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.00View SEC Filing  
10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View SEC Filing  
10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.00View SEC Filing  
9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00View SEC Filing  
9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.00View SEC Filing  
9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View SEC Filing  
9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View SEC Filing  
9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.00View SEC Filing  
8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00View SEC Filing  
8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.00View SEC Filing  
8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.00View SEC Filing  
8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.00View SEC Filing  
7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View SEC Filing  
7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View SEC Filing  
7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View SEC Filing  
7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View SEC Filing  
6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View SEC Filing  
6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View SEC Filing  
6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View SEC Filing  
6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View SEC Filing  
6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View SEC Filing  
6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View SEC Filing  
5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View SEC Filing  
5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View SEC Filing  
5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View SEC Filing  
5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View SEC Filing  
5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View SEC Filing  
5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View SEC Filing  
5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View SEC Filing  
5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View SEC Filing  
5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View SEC Filing  
5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View SEC Filing  
5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View SEC Filing  
2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View SEC Filing  
2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View SEC Filing  
2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View SEC Filing  
11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View SEC Filing  
11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View SEC Filing  
11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View SEC Filing  
11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View SEC Filing  
11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View SEC Filing  
11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Genomic Health (NASDAQ GHDX) News Headlines

Source:
DateHeadline
Genomic Health drawing takeover interest; shares ahead 20%Genomic Health drawing takeover interest; shares ahead 20%
seekingalpha.com - December 14 at 4:55 PM
Why Genomic Health, Inc. Skyrocketed TodayWhy Genomic Health, Inc. Skyrocketed Today
www.fool.com - December 14 at 2:59 PM
Genomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 SharesGenomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 Shares
www.americanbankingnews.com - December 13 at 6:20 PM
J P Morgan Chase & Co Lowers Genomic Health (GHDX) to UnderweightJ P Morgan Chase & Co Lowers Genomic Health (GHDX) to Underweight
www.americanbankingnews.com - December 13 at 8:54 AM
Genomic Health (GHDX) Oncotype DX Score Test Data PositiveGenomic Health (GHDX) Oncotype DX Score Test Data Positive
finance.yahoo.com - December 12 at 9:58 AM
ETFs with exposure to Genomic Health, Inc. : December 11, 2017ETFs with exposure to Genomic Health, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 5:31 PM
Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease ContinuumGenomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum
finance.yahoo.com - December 11 at 10:15 AM
Financial Analysis: Genomic Health (GHDX) vs. Advaxis (ADXS)Financial Analysis: Genomic Health (GHDX) vs. Advaxis (ADXS)
www.americanbankingnews.com - December 11 at 5:38 AM
Genomic Health-Janssen Pharma Tie Up, GPS Test in FocusGenomic Health-Janssen Pharma Tie Up, GPS Test in Focus
finance.yahoo.com - December 8 at 9:31 AM
Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug DevelopmentGenomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug Development
finance.yahoo.com - December 6 at 9:40 AM
Genomic Health, Inc. (GHDX) Given Average Recommendation of "Hold" by AnalystsGenomic Health, Inc. (GHDX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 4 at 3:46 AM
ETFs with exposure to Genomic Health, Inc. : December 1, 2017ETFs with exposure to Genomic Health, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 4:52 PM
Genomic Health-Cleveland Diagnostics Deal to Boost Test SuiteGenomic Health-Cleveland Diagnostics Deal to Boost Test Suite
finance.yahoo.com - November 30 at 10:00 AM
Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 10:00 AM
Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Tests Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer StagingGenomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging
finance.yahoo.com - November 30 at 10:00 AM
Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer TestsGenomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests
finance.yahoo.com - November 28 at 9:12 AM
Genomic Health, Inc. (GHDX) Expected to Post Quarterly Sales of $89.51 MillionGenomic Health, Inc. (GHDX) Expected to Post Quarterly Sales of $89.51 Million
www.americanbankingnews.com - November 28 at 8:30 AM
$0.09 EPS Expected for Genomic Health, Inc. (GHDX) This Quarter$0.09 EPS Expected for Genomic Health, Inc. (GHDX) This Quarter
www.americanbankingnews.com - November 26 at 11:16 AM
Genomic Health to Present at the 29th Annual Piper Jaffray Healthcare ConferenceGenomic Health to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 21 at 7:04 PM
Genomic Health Cancer Diagnostic Tests Grow Amid Cost WoesGenomic Health Cancer Diagnostic Tests Grow Amid Cost Woes
finance.yahoo.com - November 17 at 5:38 PM
Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATEBiocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE
finance.yahoo.com - November 16 at 2:43 PM
Canaccord Genuity Reaffirms "Buy" Rating for Genomic Health, Inc. (GHDX)Canaccord Genuity Reaffirms "Buy" Rating for Genomic Health, Inc. (GHDX)
www.americanbankingnews.com - November 15 at 11:43 AM
Genomic Health, Inc. (GHDX) Expected to Earn FY2017 Earnings of ($0.09) Per ShareGenomic Health, Inc. (GHDX) Expected to Earn FY2017 Earnings of ($0.09) Per Share
www.americanbankingnews.com - November 15 at 6:56 AM
Brokers Set Expectations for Genomic Health, Inc.s Q1 2018 Earnings (GHDX)Brokers Set Expectations for Genomic Health, Inc.'s Q1 2018 Earnings (GHDX)
www.americanbankingnews.com - November 14 at 9:26 AM
FY2017 EPS Estimates for Genomic Health, Inc. Cut by Jefferies Group (GHDX)FY2017 EPS Estimates for Genomic Health, Inc. Cut by Jefferies Group (GHDX)
www.americanbankingnews.com - November 13 at 3:36 AM
Q4 2017 EPS Estimates for Genomic Health, Inc. (GHDX) Reduced by AnalystQ4 2017 EPS Estimates for Genomic Health, Inc. (GHDX) Reduced by Analyst
www.americanbankingnews.com - November 10 at 8:48 AM
Genomic Health, Inc. (GHDX) Cut to Sell at ValuEngineGenomic Health, Inc. (GHDX) Cut to Sell at ValuEngine
www.americanbankingnews.com - November 10 at 12:58 AM
Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business ProgressGenomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress
finance.yahoo.com - November 9 at 6:04 AM
Genomic Health reports 3Q lossGenomic Health reports 3Q loss
finance.yahoo.com - November 9 at 6:04 AM
Edited Transcript of GHDX earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of GHDX earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 6:04 AM
Genomic Health, Inc. (GHDX) Given Average Rating of "Hold" by BrokeragesGenomic Health, Inc. (GHDX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 9 at 3:38 AM
$87.06 Million in Sales Expected for Genomic Health, Inc. (GHDX) This Quarter$87.06 Million in Sales Expected for Genomic Health, Inc. (GHDX) This Quarter
www.americanbankingnews.com - November 9 at 2:46 AM
Genomic Health, Inc. (GHDX) Insider Sells $44,831.29 in StockGenomic Health, Inc. (GHDX) Insider Sells $44,831.29 in Stock
www.americanbankingnews.com - November 8 at 7:58 PM
GHDX Crosses Below Key Moving Average LevelGHDX Crosses Below Key Moving Average Level
www.nasdaq.com - November 8 at 7:59 AM
Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
finance.yahoo.com - November 1 at 8:36 PM
Genomic Health, Inc. (GHDX) Scheduled to Post Earnings on WednesdayGenomic Health, Inc. (GHDX) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - November 1 at 8:08 PM
Genomic Health, Inc. (GHDX) Set to Announce Quarterly Earnings on MondayGenomic Health, Inc. (GHDX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 9:20 AM
Equities Analysts Set Expectations for Genomic Health, Inc.s Q3 2017 Earnings (GHDX)Equities Analysts Set Expectations for Genomic Health, Inc.'s Q3 2017 Earnings (GHDX)
www.americanbankingnews.com - October 23 at 1:50 AM
Genomic Health, Inc. (GHDX) Rating Reiterated by Jefferies Group LLCGenomic Health, Inc. (GHDX) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 21 at 5:26 PM
Genomic Health, Inc. (GHDX) Expected to Announce Quarterly Sales of $87.06 MillionGenomic Health, Inc. (GHDX) Expected to Announce Quarterly Sales of $87.06 Million
www.americanbankingnews.com - October 21 at 2:54 PM
Financial Analysis: Genomic Health (GHDX) & Its PeersFinancial Analysis: Genomic Health (GHDX) & Its Peers
www.americanbankingnews.com - October 17 at 2:08 PM
Genomic Health, Inc. (GHDX) Receives Consensus Recommendation of "Hold" from BrokeragesGenomic Health, Inc. (GHDX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 15 at 4:46 AM
Genomic Health, Inc. (GHDX) Raised to Hold at Zacks Investment ResearchGenomic Health, Inc. (GHDX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - October 13 at 1:54 PM
Genomic Health, Inc. (GHDX) COO Sells $159,650.00 in StockGenomic Health, Inc. (GHDX) COO Sells $159,650.00 in Stock
www.americanbankingnews.com - October 11 at 7:50 PM
Zacks Investment Research Lowers Genomic Health, Inc. (GHDX) to SellZacks Investment Research Lowers Genomic Health, Inc. (GHDX) to Sell
www.americanbankingnews.com - October 8 at 7:20 PM
Genomic Healths Cost Pressure Mounts, Cancer Tests StrongGenomic Health's Cost Pressure Mounts, Cancer Tests Strong
finance.yahoo.com - October 5 at 11:45 PM
Genomic Health, Inc. (GHDX) Earns "Buy" Rating from Canaccord GenuityGenomic Health, Inc. (GHDX) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - October 1 at 5:14 PM
Contrasting Genomic Health (GHDX) & Inovio Pharmaceuticals (INO)Contrasting Genomic Health (GHDX) & Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - September 28 at 10:50 PM
Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 27, 2017Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 27, 2017
finance.yahoo.com - September 27 at 8:34 AM
ETFs with exposure to Genomic Health, Inc. : September 26, 2017ETFs with exposure to Genomic Health, Inc. : September 26, 2017
finance.yahoo.com - September 26 at 6:50 PM

SEC Filings

Genomic Health (NASDAQ:GHDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Genomic Health (NASDAQ:GHDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Genomic Health (NASDAQ GHDX) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.